| ATPC 0.1157 65.29% | MTEN 0.0323 -8.50% | OCG 0.0098 -16.95% | SOXS 2.065 -9.43% | AUID 2.295 131.23% | CJMB 5.0131 347.60% | IVP 0.0477 -41.83% | ZSL 2.9499 4.61% | SLV 82.9899 -1.86% | NVDA 187.4686 2.36% | SPHL 16.5703 636.46% | INTC 49.117 0.81% | APLT 0.1014 1.50% | BNKK 4.34 56.12% | DVLT 0.7402 3.06% | SOXL 60.9973 10.14% | TQQQ 55.57 3.23% | ASST 0.9927 -3.62% | BYND 1.02 6.04% | TZA 5.905 -4.14% | GRAB 4.41 -4.75% | TSLL 18.3793 1.71% | EEM 58.31 0.97% | ONDS 13.055 -3.72% | BBAI 6.375 1.84% | TSLS 5.145 -0.87% | SPY 694.78 0.64% | IBRX 3.6479 20.79% | MSTX 4.96 -4.62% | NOK 6.725 5.74% | DUST 5.775 -0.43% | AMD 236.295 5.68% | SIDU 3.595 -4.13% | RZLV 4.69 15.52% | BITO 13.39 -1.25% | IBIT 54.725 -1.29% | JTAI 0.4753 4.55% | AAL 15.765 4.13% | NVD 7.065 -4.66% | VALE 14.755 0.99% | QQQ 626.2588 1.08% | PLUG 2.34 -0.43% | SQQQ 64.7999 -3.20% | TSM 349.625 6.88% | XLF 54.585 0.80% | TSLA 443.0155 0.87% | CRWV 98.9301 10.17% | SEGG 1.0905 17.68% | CAN 0.8098 -7.46% | PTHL 0.5285 20.17%

Nutex Health Inc. (NASDAQ:NUTX) Surpasses Earnings Expectations

Nutex Health Inc. (NASDAQ:NUTX) is a physician-led, integrated healthcare delivery system. It operates 24 micro hospitals and hospital outpatient departments across 11 states, along with primary care-centric, risk-bearing physician networks. The company focuses on providing efficient healthcare services, which is reflected in its recent financial performance.

On November 19, 2025, Nutex Health reported earnings that exceeded expectations. The company achieved a revenue of approximately $244 million, surpassing the estimated $222 million. This success is part of a broader financial upturn for the first half of 2025, where total revenue reached $455.8 million, a 217.5% increase from the same period in 2024.

Nutex Health's net income for the first half of 2025 was $3.5 million, a significant improvement from a net loss of $0.7 million in 2024. This $4.2 million increase highlights the company's turnaround. The diluted income per share rose to $0.55, contrasting with a loss per share of $0.15 the previous year, indicating improved profitability for shareholders.

The company's EBITDA for the first half of 2025 was $51.1 million, up from $15.6 million in 2024, representing a 227.4% increase. Adjusted EBITDA saw an even more dramatic rise, reaching $144.4 million, a 2144.2% increase from $6.4 million in 2024. This growth underscores Nutex Health's operational efficiency and financial health.

Nutex Health's financial metrics reflect its market position. With a P/E ratio of approximately 10.43 and a price-to-sales ratio of about 0.70, the company is valued attractively compared to its earnings and sales. The enterprise value to sales ratio is roughly 0.97, and the enterprise value to operating cash flow ratio is approximately 5.84, indicating efficient cash flow management. The debt-to-equity ratio of approximately 0.94 and a current ratio of around 2.43 demonstrate a balanced approach to debt and strong liquidity.

Published on: November 19, 2025